{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:10Z","timestamp":1791406990053,"version":"4.3.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014240","name":"American Kidney Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011751","name":"Northwest Kidney Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["T32DK007467"],"award-info":[{"award-number":["T32DK007467"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jdiacomp.2022.108204","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T11:24:32Z","timestamp":1651317872000},"page":"108204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes"],"prefix":"10.1016","volume":"36","author":[{"given":"Christine P.","family":"Limonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio N.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulaxmi","family":"Trikudanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila R.","family":"Zelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2022.108204_bb0005","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Ref lections from a diabetes care editors' expert forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotranspo","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01053-0","article-title":"Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","volume":"19","author":"Yang","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0050","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0055","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0070","article-title":"National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey 2013-2014, 2015-2016, 2017- March 2020 documentation files","author":"Centers for Disease Control and Prevention (CDC)","year":"2020"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0075","series-title":"Analytic guidance and brief overview for the 2017-March 2020 pre-pandemic data files","author":"NHANES","year":"2021"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0080","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0085","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"De Boer","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0090","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2215\/CJN.03700417","article-title":"Diabetes and CKD in the United States population, 2009\u20132014","volume":"12","author":"Zelnick","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0095","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/edm2.76","article-title":"The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States","volume":"2","author":"Weng","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0115","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FJC.0000000000000864","article-title":"Antihyperglycemic therapies with expansions of US Food and Drug Administration indications to reduce cardiovascular events: prescribing patterns within an Academic Medical Center","volume":"76","author":"Hamid","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clinthera.2020.12.015","article-title":"Prescribing in type 2 diabetes patients with and without cardiovascular disease history: a descriptive analysis in the UK CPRD","volume":"43","author":"Farmer","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/dom.13877","article-title":"Trends in antidiabetic drug utilization and expenditure in Denmark: a 22-year nationwide study","volume":"22","author":"Bang","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0135","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR\u00ae research to practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.121.021084","article-title":"Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus","volume":"10","author":"Nargesi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-021-02381-3","article-title":"Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study","volume":"22","author":"Jeong","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0150","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/dom.13710","article-title":"Real-world prevalence of the inclusion criteria for the LEADER trial: data from a national general practice network","volume":"21","author":"Hinton","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0160","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.2337\/dc20-2977","article-title":"Second-line therapy for type 2 diabetes management: the treatment\/benefit paradox of cardiovascular and kidney comorbidities","volume":"44","author":"McCoy","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0229621","article-title":"Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study","volume":"15","author":"Knudsen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0175","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0185","first-page":"1","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: barriers and solutions for improving uptake in routine clinical practice","volume":"2022","author":"Khunti","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0195","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jamanetworkopen.2020.20969","article-title":"Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the medicare part D program","volume":"3","author":"Luo","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jcjd.2018.09.001","article-title":"Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study","volume":"43","author":"Carretero G\u00f3mez","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0205","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00125-018-4547-9","article-title":"Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies","volume":"61","author":"Schernthaner","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0210","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-020-01369-x","article-title":"Diabetes complications in racial and ethnic minority populations in the USA","volume":"21","author":"Haw","year":"2021","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jdiacomp.2022.108204_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2019.11.001","article-title":"Socioeconomic inequalities and type 2 diabetes complications: a systematic review","volume":"46","author":"Tatulashvili","year":"2020","journal-title":"Diabetes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:16:55Z","timestamp":1778797015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872722001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1056872722001064"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108204","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108204"}}